Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

Background There is growing evidence suggesting that the occurrence of immune-related
adverse events (irAEs) may be a predictor of immune checkpoint inhibitor efficacy. Whether …

Aim Immune checkpoint inhibitors (ICIs) have updated the treatment landscape for patients
with advanced malignancies, while their clinical prospect was hindered by severe immune …

Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of a
variety of cancers, however their therapeutic potential is limited by abstruse immune related …

Background and Objective Although anti-programmed cell death protein 1 (PD-1) antibodies
have exerted remarkable anticancer activity in non-small cell lung cancer (NSCLC), it …

Monoclonal antibodies (mAbs) blocking the PD-1/PD-L1 interface have shown remarkable
success in treating malignancies, but they may also initiate lethal immune-related adverse …

Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of many cancer
types, including head and neck cancers (HNC). When checkpoint and partner proteins bind …

Although indications for immune checkpoint inhibitors (ICIs) have dramatically increased in
the past decade, ICIs have been associated with autoinflammatory immune-related adverse …

The emergence of tyrosine kinase inhibitors and immune checkpoint inhibitors has paved a
new era for the management of non‐small cell lung cancer, which has for many years lacked …

Simple Summary Immune-modulating cancer treatments have proved to be highly effective
in a wide range of tumour types. They interrupt the usual communication between cells in …